002038.SZ

Beijing SL Pharmaceutical Co., Ltd. [002038.SZ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

002038.SZ Stock Summary

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

Top 10 Correlated ETFs

002038.SZ

Top 10 Correlated Stocks

002038.SZ

In the News

002038.SZ Financial details

Company Rating

Buy

Market Cap

8.67B

Income

311.05M

Revenue

999.82M

Book val./share

5.53

Cash/share

0.85

Dividend

0.1

Dividend %

1.06%

Employees

757

Optionable

Shortable

Yes

Earnings

24 Apr 2024

P/E

31.55

Forward P/E

PEG

-12.21

P/S

9.76

P/B

1.73

P/C

9.66

P/FCF

-1312.44

Quick Ratio

4.58

Current Ratio

7.85

Debt / Equity

-0

LT Debt / Equity

-0

EPS (TTM)

0.3

EPS next Y

EPS next Q

EPS this Y

-43.9%

EPS next Y

EPS next 5Y

EPS last 5Y

-22.64%

Revenue last 5Y

-13.49%

Revenue Q/Q

-32.69%

EPS Q/Q

-99.64%

SMA20

-10.15%

SMA50

-2.89%

SMA100

-25.24%

Inst Own

Inst Trans

ROA

ROE

ROC

0.06%

Gross Margin

82%

Oper. Margin

36%

Profit Margin

31%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

7.05-16.09

52W High

-48.69%

52W Low

+17.29%

RSI

37.29

Rel Volume

0.26

Avg Volume

22.07M

Volume

5.66M

Perf Week

-4.42%

Perf Month

-9.68%

Perf Quarter

-34.58%

Perf Half Y

-47.03%

Beta

0.346

Volatility

0.14%, 0.4%

Prev Close

-1.08%

Price

8.21

Change

-1.68%

002038.SZ Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.16	1.96	1.08	1.18	1.02
Net income per share	0.83	0.47	0.35	0.41	0.23
Operating cash flow per share	0.71	0.64	0.4	0.45	0.38
Free cash flow per share	0.38	0.38	0.16	0.22	0.22
Cash per share	1.75	1.35	0.82	0.96	0.72
Book value per share	6.57	4.64	4.84	5.17	5.32
Tangible book value per share	5.56	4.04	4.16	4.33	4.38
Share holders equity per share	6.57	4.64	4.84	5.17	5.32
Interest debt per share	0.03	0	0.01	0	-0.03
Market cap	16.2B	13.62B	10.38B	11.11B	8.44B
Enterprise value	15.03B	12.36B	9.72B	10.28B	7.85B
P/E ratio	28.34	27.98	28.45	26.07	36.03
Price to sales ratio	7.47	6.71	9.32	9.14	8.04
POCF ratio	33.38	20.46	24.95	23.9	21.66
PFCF ratio	62.82	34.65	64.9	48.77	37.31
P/B Ratio	3.6	2.83	2.09	2.09	1.54
PTB ratio	3.6	2.83	2.09	2.09	1.54
EV to sales	6.93	6.09	8.73	8.46	7.47
Enterprise value over EBITDA	19.82	19.24	20.45	17.36	18.5
EV to operating cash flow	30.98	18.57	23.37	22.13	20.14
EV to free cash flow	58.3	31.45	60.78	45.14	34.68
Earnings yield	0.04	0.04	0.04	0.04	0.03
Free cash flow yield	0.02	0.03	0.02	0.02	0.03
Debt to equity	0	0	0	0	-0.01
Debt to assets	0	0	0	0	0
Net debt to EBITDA	-1.54	-1.96	-1.38	-1.39	-1.4
Current ratio	6.36	8.61	7.01	7.07	6.92
Interest coverage	32.73	5.97K	1.17K	2.03K	2.57K
Income quality	0.86	1.39	1.15	1.1	1.71
Dividend Yield	0.02	0.02	0.02	0.01	0.01
Payout ratio	0.6	0.42	0.56	0.24	0.44
Sales general and administrative to revenue	0.01	0.01	0.02	0.01	0.02
Research and developement to revenue	0.03	0.06	0.17	0.16	0.15
Intangibles to total assets	0.14	0.12	0.13	0.15	0.17
Capex to operating cash flow	-0.47	-0.41	-0.62	-0.51	-0.42
Capex to revenue	-0.1	-0.13	-0.23	-0.2	-0.16
Capex to depreciation	-4.07	-3.56	-2.86	-2.37	-1.44
Stock based compensation to revenue	0	0	-0.02	-0.01	0.01
Graham number	11.1	7.01	6.22	6.94	5.23
ROIC	0.13	0.1	0.07	0.08	0.04
Return on tangible assets	0.13	0.11	0.08	0.09	0.05
Graham Net	2.17	1.62	0.94	0.99	0.7
Working capital	2.36B	2.53B	1.89B	1.97B	1.71B
Tangible asset value	3.81B	4.18B	4.27B	4.45B	4.5B
Net current asset value	2.33B	2.46B	1.8B	1.86B	1.6B
Invested capital	0	0	0	0	-0.01
Average receivables	829.85M	844.38M	745.59M	591.94M	470.18M
Average payables	188.22M	221.73M	179.22M	185.66M	183.79M
Average inventory	263.48M	179.81M	110.19M	118.43M	130.82M
Days sales outstanding	142.72	151.28	213.19	160.43	141.25
Days payables outstanding	215.73	156.1	401.86	380.56	409.7
Days of inventory on hand	204.59	94.75	250.22	248.2	318.17
Receivables turnover	2.56	2.41	1.71	2.28	2.58
Payables turnover	1.69	2.34	0.91	0.96	0.89
Inventory turnover	1.78	3.85	1.46	1.47	1.15
ROE	0.13	0.1	0.07	0.08	0.04
Capex per share	-0.33	-0.26	-0.25	-0.23	-0.16

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.27	0.22	0.29	0.28	0.19
Net income per share	0.07	-0.01	0.2	0.11	0
Operating cash flow per share	0.07	-0.01	0.2	0.08	0.04
Free cash flow per share	0.04	-0.09	0.17	0.03	0
Cash per share	1.03	0.72	0.82	0.82	0.85
Book value per share	5.3	5.32	5.52	5.53	5.53
Tangible book value per share	4.41	4.38	4.56	4.5	4.49
Share holders equity per share	5.3	5.32	5.52	5.53	5.53
Interest debt per share	0	-0.03	-0.02	-0.02	-0.01
Market cap	8.45B	8.44B	8.85B	10.37B	12.72B
Enterprise value	7.54B	7.85B	8.14B	9.66B	11.98B
P/E ratio	29.1	-323.87	10.95	22.49	7.87K
Price to sales ratio	30.99	37.84	29.83	36.13	65.86
POCF ratio	116.41	-1.3K	43.8	133.51	306.15
PFCF ratio	191.99	-95.49	51.86	358.55	18.03K
P/B Ratio	1.55	1.54	1.56	1.82	2.24
PTB ratio	1.55	1.54	1.56	1.82	2.24
EV to sales	27.65	35.17	27.46	33.67	62.05
Enterprise value over EBITDA	143.53	145.86	234.92	27.66	-53.8
EV to operating cash flow	103.85	-1.2K	40.32	124.43	288.45
EV to free cash flow	171.27	-88.76	47.74	334.17	16.99K
Earnings yield	0.01	0	0.02	0.01	0
Free cash flow yield	0.01	-0.01	0.02	0	0
Debt to equity	0	-0.01	0	0	0
Debt to assets	0	0	0	0	0
Net debt to EBITDA	-17.36	-11.06	-20.28	-2.02	3.3
Current ratio	7.43	6.92	7.29	7.37	7.85
Interest coverage	1.84K	718.95	-929.7	0	0
Income quality	1	1	1	0.67	102.84
Dividend Yield	0	0.01	0	0.01	0
Payout ratio	0	-15.76	0	0.89	0
Sales general and administrative to revenue	0.27	-0.24	0.09	-0.08	0.48
Research and developement to revenue	0.12	0.29	0.12	0.09	0.21
Intangibles to total assets	0.16	0.17	0.16	0.18	0.18
Capex to operating cash flow	-0.39	12.57	-0.16	-0.63	-0.98
Capex to revenue	-0.1	-0.37	-0.11	-0.17	-0.21
Capex to depreciation	-0.98	-2.8	-0.94	-1.47	0.61
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.9	0.87	4.94	3.74	0.22
ROIC	0.01	0	0.04	0.02	0
Return on tangible assets	0.01	0	0.04	0.02	0
Graham Net	1.02	0.7	0.81	0.77	0.79
Working capital	2.06B	1.71B	1.82B	1.76B	1.79B
Tangible asset value	4.53B	4.5B	4.69B	4.62B	4.62B
Net current asset value	1.95B	1.6B	1.71B	1.64B	1.67B
Invested capital	0	-0.01	0	0	0
Average receivables	468.78M	434.21M	403.37M	372.88M	334.63M
Average payables	184.69M	179.78M	174.68M	174.73M	172.27M
Average inventory	147.8M	140.6M	160.74M	172.27M	154.75M
Days sales outstanding	152.45	163.88	121.49	108.35	150.92
Days payables outstanding	373.25	604.66	378.3	283.81	279.47
Days of inventory on hand	293.89	469.57	403.4	257.39	248.53
Receivables turnover	0.59	0.55	0.74	0.83	0.6
Payables turnover	0.24	0.15	0.24	0.32	0.32
Inventory turnover	0.31	0.19	0.22	0.35	0.36
ROE	0.01	0	0.04	0.02	0
Capex per share	-0.03	-0.08	-0.03	-0.05	-0.04

002038.SZ Dividend History

002038.SZ Frequently Asked Questions

What is Beijing SL Pharmaceutical Co., Ltd. stock symbol ?

Beijing SL Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002038.SZ

What is Beijing SL Pharmaceutical Co., Ltd. stock quote today ?

Beijing SL Pharmaceutical Co., Ltd. stock price is $8.21 today.

Is Beijing SL Pharmaceutical Co., Ltd. stock public?

Yes, Beijing SL Pharmaceutical Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 22.07M
Market Capitalization 8.67B
Employee 757
CEO Dr. Mingbo Xu
Headquarters Beijing,CN
IPO Date 2004-09-09
Website https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.